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Abstract: Background: Zanthoxylum armatum DC. (ZA) is a traditional Asian culinary spice and 
medicinal compound, which is rich in monoterpenes and hydroxy α-sanshool. Mechanistic 
interactions with the monoamine, cholinergic and cannabinoid neurotransmission systems, as well 
as transient receptor potential (TRP) and potassium ion channels, may predispose ZA to modulate 
human brain function. Objectives: To investigate the effects of a single dose and 56-days 
supplementation with a lipid extract of ZA on cognitive function, mood and cerebral blood-flow 
(CBF) parameters in the pre-frontal cortex during cognitive task performance. Design: Double-blind, 
randomized, parallel groups study with N = 82 healthy males and females between the ages of 30 
and 55 years. Assessments were undertaken pre-dose and at 1, 3 and 5 hours post-dose on the first 
(Day 1) and last (Day 56) days of supplementation. Results: A single dose of ZA (Day 1) resulted in 
acute improvements on a ‘Speed of Attention’ factor and the Rapid Visual Information Processing 
(RVIP) task, in comparison to placebo. However, following ZA participants were less accurate on 
the name-to-face recall task. After 56 days of ZA consumption (Day 56), speed was enhanced on a 
global ‘Speed of Performance’ measure, comprising data from all of the timed tasks in the 
computerized battery. Participants also completed more correct Serial 3s Subtractions at the 3 hours 
assessment and were less mentally fatigued throughout the day than participants consuming 
placebo. These effects were complemented on both Day 1 and Day 56 by modulation of CBF 
parameters, as assessed by Near Infrared Spectroscopy (NIRS). The primary finding here was a 
reduced hemodynamic response during the RVIP task. Conclusion: ZA improves aspects of cognitive 
performance, in particular the speed of performing tasks, in healthy humans and results in 
concomitant reductions in hemodynamic responses in the frontal cortex during task performance. 
The findings suggest an increase in neural efficiency following ZA. 
Keywords: Nepalese pepper; cognition; cerebral blood flow; hydroxy-α-sanshool 
 
1. Introduction 
The plant species Zanthoxylum armatum DC. (ZA; also known as Nepalese or Timur pepper) is 
from the Rutaceae or citrus, family and its bark, seeds and fruits have a long history as sources of 
medicinal treatments. This is particularly prevalent in Chinese, Nepalese and Ayurvedic medical 
systems with indications including as a treatment for depression, gastro-intestinal and digestive 
disorders and as a topical treatments for toothache and skin irritation/wounds [1–3]. It is also one of 
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several species of the Zanthoxylum genus generically known as Szechuan pepper; a traditional 
Chinese and Nepalese culinary spice comprising the fruit pericarp which is typically added to wok 
and dumpling dishes to provide a characteristic grapefruit-like taste and flavor and a tingling 
numbness in the mouth. 
Whilst the various tissues from ZA have complex phytochemistry, the tingling mouth sensation, 
and any gastro-intestinal or dental applications, are related to the presence of a number of alkamides 
and unsaturated fatty acid amides; most notably hydroxy α-sanshool (see Figure 1) and related 
structures [4]. The alkamide group of compounds, which are also found in 300+ species from the 
Zanthoxylum, Acmella (Spilanthes), Anacyclus, Echinacea and Heliopsis genera, typically also have 
insecticidal, larvicidal and antimicrobial properties and act as plant growth factors [4]. In mammals, 
they have anti-inflammatory, immunomodulatory and analgesic properties and may underlie the 
putative medicinal effects of plants such as Echinacea and ‘maca’ (Lepidium meyeni) [1,4]. Evidence 
suggests that alkamides can readily cross the skin, oral and gut mucosa and that they can traverse 
the blood brain barrier [5]. In rodent models, the alkamide riparin II has been shown to reduce anxiety 
[6] and attenuate depression via monoaminergic mechanisms [7]. 
 
Figure 1. Chemical structure of hydroxy α-sanshool. 
In a medicinal context, ZA is most likely to be encountered as a component of the traditional 
Japanese herbal medicine Daikenchuto, which comprises ginger rhizome, ginseng root, rice gluten 
and Zanthoxylum fruit. Daikenchuto is generally indicated for gastrointestinal disorders [8], with 
some evidence of efficacy following abdominal surgery [9,10]. In a study assessing the 
pharmacokinetics of Daikenchuto, it was demonstrated that hydroxy α-sanshool achieved by far the 
highest plasma levels of the six compounds measured. Its bioavailability peaked after 30 minutes 
with a mean half-life of approximately 2 hours [11]. A single study [12] demonstrated that 
Daikenchuto, administered for 3 days, improved mouse learning and memory and attenuated the 
cognitive decrements associated with the muscarinic receptor antagonist scopolamine. The learning 
and memory effects were also evident following both the ZA and hydroxy α-sanshool components 
by themselves, confirming that hydroxy α-sanshool was the active component in terms of learning 
and memory benefits. 
In mechanistic terms, the gastrointestinal effects of Daikenchuto have been attributed to 
increased acetylcholine release [13]. In line with this, an attenuation of the learning and memory 
decrements associated with scopolamine in rodents suggests cholinergic activity as a potential 
mechanism of any brain function effects of Daikenchuto and its active ingredients [12]. However, it 
is also notable that alkamides such as γ-sanshool have been shown to interact with cannabinoid CB1 
and CB2 receptors; due to the structural similarity between the sanshool group and endocannabinoids 
[14]. In general, the oral sensations associated with a variety of spices and food additives are 
attributable to interactions with differing transient receptor potential (TRP) channels. These plasma 
membrane ion channels modulate the entry of positively charged ions into numerous cell types and 
mediate the perception of sensations such as pressure, temperature and pain [15]. The tingling 
numbness associated with hydroxy α-sanshool is specifically due to interactions with TRPV1 (also 
known as the vanilloid receptor) and TRPA1 receptors in sensory neurons, which result in an influx 
of Ca2+ [16]. Hydroxy α-sanshool also inhibits members of the two-pore domain potassium ion 
channel  family (designated as the KCNK family by the Human Genome Organization) that are 
sensitive to mechanical stimuli, pH, signaling lipids and other G-protein receptor ligands including 
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neurotransmitters and anesthetics. In this regard hydroxy α-sanshool specifically inhibits family 
members TASK-1 (TWIK-related acid-sensitive potassium-1), TASK-3 and TRESK [4]. Interestingly, 
evidence shows that both the TRP and KCNK ion channels that are modulated by hydroxy α-
sanshool are widely distributed in cognition relevant brain regions [17,18]. 
Alongside significant levels of monoterpenes, which have been shown to exert independent 
beneficial effects on cognitive function [19,20], it is possible that an extract rich in hydroxy α-sanshool 
will have multifarious effects on human brain function. The current double-blind, randomized, 
parallel groups study therefore investigated the effects of a single 80 mg dose and 56-days 
supplementation with a lipid extract of ZA on cognitive function, mood and cerebral blood-flow 
parameters in the frontal cortex. 
2. Methods 
2.1. Design 
The study adopted a double-blind, placebo-controlled, parallel-groups design, in which the 
acute and chronic effects of Zanthoxylum armatum DC. (Nepalese pepper) extract (ZA) and placebo 
were assessed pre-dose and at 1, 3 and 5 hours post-dose on the first day (i.e., acute effects) and 
following 56 days (+/−3 days) consumption of the intervention. An optional, concomitant 
investigation of the cerebral blood-flow effects of the extract was carried out in ~50% of the total 
sample. 
2.2. Participants 
The final sample comprised a total of 82 participants, aged 30 to 55 years, who self-reported 
themselves to be in good health. Participants were excluded from the study if they: Had any pre-
existing medical condition/illness or were currently taking prescription medications which might 
have an impact on their ability to take part in the study; were taking any dietary supplements 
including omega fatty acids/fish oils; had high blood pressure (systolic over 159 mm Hg or diastolic 
over 99 mm Hg); had a Body Mass Index (BMI) outside of the range 18–35 kg/m2; were pregnant, 
seeking to become pregnant or lactating; had learning difficulties or dyslexia; had an uncorrected 
visual impairment; were smokers or regular consumers of nicotine containing products; had a history 
of alcohol or drug abuse; consumed caffeine in excess of 500 mg per day; had any food 
intolerances/sensitivities; were unable to complete all of the study assessments or were non-
compliant with regards treatment consumption (<80%; although this did not apply to any 
participants in this study). 
The group demographics are shown in Table 1. below. Two participants dropped out after their 
Day 1 assessment (for reasons unrelated to treatment) and were only included in the analysis of Day 
1 data. 
A small number of data points were either missing or omitted due to incorrect performance of 
tasks. Individual sample sizes for each task (n) are shown in the data tables in the Online 
Supplementary Materials. 
Table 1. Demographics of Zanthoxylum armatum DC. (ZA)and placebo groups. There were no 
significant differences between groups on any measure. 
 Placebo ZA 
Number of Participants 42 41 
Age at Enrolment (Years) 41.76 43.15 
Sex F30/M12 F33/M8 
Years in Education 16.2 15.9 
Portions of Fruit & Veg/day 4.37 4.42 
Alcohol consumption daily (units) 0.84 0.72 
Caffeine Consumption Score (mg) 149.90 179.67 
Average BP Systolic (mm Hg) 116.92 116.88 
Average BP Diastolic (mm Hg) 78.88 79.21 
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Average Heart Rate (Beats per min) 73.11 72.22 
Weight (KG) 69.51 73.15 
Height (cm) 168.51 167.47 
BMI 24.47 25.92 
Near-infrared Spectroscopy (NIRS) Cerebral Blood-Flow Participants 
A sub-set of 41 participants (21 placebo, 20 ZA) took part in the cerebral blood-flow (CBF) 
assessment. . Two participants in the placebo group were excluded from the assessment of the global 
effects of the treatments on resting CBF on Day 1/Day 56 and the acute CBF effects on Day 1 due to 
aberrant pre-dose baseline data due to a technical issue. The data from both participants was included 
in the assessment of hemodynamic responses on Day 1 and Day 56 (which used pre-task resting data 
as the baseline). 
The study received ethical approval from the Northumbria University Psychology department 
(within the faculty of Health and Life Sciences) staff ethics committee (Reference 7905) and was 
conducted according to the Declaration of Helsinki (1964). All participants gave their written 
informed consent prior to their inclusion in the study. 
2.3. Treatments 
Treatments comprised 4 dark-brown soft gel capsules/day containing either: 
• Placebo (sunflower oil) 
• 2.8 g Zanthozylum armatum DC. Medium-chain triglyceride (MCT) oil extract (corresponding to 
80 mg Z.armatum DC. extract) 
The medium-chain triglyceride (MCT) oil extract of Zanthozylum armatum DC. (SaraPEPP™ Nu) 
was provided by Mibelle Group Biochemistry, Mibelle AG, Switzerland. Each 2.8 g dose contained 
alkamides including 7.8 mg hydroxy α-sanshool and monoterpenes including 5.3 mg limonene, 3.6 
mg linalool and 2.3 mg methyl cinnamate. 
Participants consumed the first and last dose of their 56-day treatment regimen under 
supervision within the laboratory. Otherwise, they consumed their treatment twice daily (2 capsules 
in the morning, 2 capsules in the evening, together with a meal) at home. The average compliance (as 
assessed by treatment diary and returned pill count) was 98%. 
A treatment guess at the end of the study showed that there was no significant difference 
between the accuracy of guessing in the two treatment groups. 
2.4. Cognitive and Mood Measures 
All cognitive tasks and mood measures were delivered via the Computerized Mental 
Performance Assessment System (COMPASS; see: www.cognitivetesting.co.uk), a software platform 
for the presentation of classic and bespoke computerized cognitive tasks, with fully randomized 
parallel versions of each task delivered at each assessment for each individual. Tasks were presented 
on a laptop PC with responses made either via a four-button response box, with mouse and cursor 
or by the keyboard’s linear number pad. The tasks and other components of each assessment are 
described below in order of completion. The timelines of each assessment are shown in Figure 2. 
Given the exploratory nature of the study, a wide spectrum of classic, widely employed cognitive 
tasks, assessing attention, secondary and working memory and executive function, were employed. 
A similar selection of tasks has previously been shown to be sensitive to nutritional interventions 
[20–24]. 
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Figure 2. Cognitive assessments. The running order of tasks and their contribution to the cognitive 
factors (to the right) and global performance measures (to the left) derived from the overall battery. 
The selection of tasks took 60 minutes to complete (with the Cognitive Demand Battery comprising 
30 minutes of this). The same assessment was completed at the pre-treatment baseline and at 1, 3 and 
5 hours post-dose during both Day 1 and Day 56. 
2.4.1. Bond-Lader Mood Scales 
The Bond-Lader Mood Scales [25] have been utilised in numerous pharmacological, 
psychopharmacological and medical trials. These scales comprise a total of sixteen 100 mm lines 
anchored at either end by antonyms (e.g., ‘alert-drowsy,’ ‘calm-excited’). Participants indicate their 
current subjective position between the antonyms on the line. Outcomes comprise three factor 
analysis derived scores—‘Alertness,’ ‘Calmness’ and ‘Contentment.’ 
2.4.2. Stimuli (Picture, Name/Face, Word) Presentation 
Fifteen black-and-white photographic images of objects were presented sequentially on screen 
for the participant to remember at the rate of 1 every 3 seconds, with a stimulus duration of one 
second. Following this a set of twelve passport-style photographic images of people were presented 
sequentially to participants. A first and last name was assigned to each photograph and presented on 
the screen underneath the person’s face. Stimulus duration was one second, with a 3-second inter-
stimulus duration. Finally, a unique set of fifteen words was presented. Words were selected at 
random from a large bank of words derived from the Medical Research Council  Psycholinguistic 
Database [26] and matched for word length, frequency, familiarity and concreteness. Stimulus 
duration was one second, as was the inter-stimulus duration. 
2.4.3. Immediate Word Recall 
Word, Picture, 
Face/Name 
presentation
Immediate Word Recall
Choice Reaction Time
Numeric Working Memory
Bond Lader Mood Scales
Delayed Name/Face Recall
Delayed Word Recall
Delayed Pic’ Recognition
Delayed Word Recognition
Corsi Blocks
Peg and Ball Task
Speed of Attention
Combined speed 
(msecs)
Working Memory 
Combined  accuracy 
(% correct)
Speed of Memory
Combined speed 
(msecs)
Episodic Memory
Combined accuracy 
(% correct)
Accuracy of Attention
Combined accuracy 
(% correct)
Cognitive Demand 
Battery
30 Minutes
4 repetitions of 
Serial 3s, Serial 
7s, RVIP, VAS
Speed of Performance
Average  Z score for 
tasks with reaction 
time data
Accuracy of Performance
Average  Z score for 
tasks with % 
accuracy data
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The participant was allowed 60 seconds to write down as many of the words as possible. The 
task was scored for number correct and errors. 
2.4.4. Numeric Working Memory 
Five random digits from 1–9 were presented sequentially for the participant to hold in memory. 
This was followed by a series of 30 probe digits (15 targets and 15 distractors) for each of which the 
participant indicated whether or not it had been in the original series by a simple key press. The task 
consisted of 3 separate trials. Accuracy (% correct) and mean reaction time (ms) were recorded. 
2.4.5. Corsi Blocks Task 
In this task, nine identical blue squares appeared on screen in non-overlapping random 
positions. A set number of blocks changed color from blue to red in a randomly generated sequence. 
The cursor was locked in position until the entire sequence had been presented, at which point the 
participants were instructed to repeat the sequence by clicking on the blocks using the mouse and 
cursor. The task was repeated five times at each level of difficulty. The sequence span increased from 
4 upwards, until the participant could no longer correctly recall the sequence, resulting in a span 
measure of nonverbal working memory, calculated by averaging the level of the last five correctly 
completed trials. 
2.4.6. Choice Reaction Time (CRT) 
The Choice Reaction Task (CRT) task required participants to indicate, by pressing the ‘left’ or 
‘right’ response box button, the direction of the arrow presented on the computer screen. Fifty stimuli 
(arrows) were presented, with a randomly varying delay of 1 to 3 sec between stimuli. The task took  
approximately2 minutes to complete, depending on participant reaction time. The task wass scored 
for % correct responses and reaction time (ms). 
2.4.7. Cognitive Demand Battery  
Multiple completions of this 10 minutes battery of tasks reliably increases self-ratings of mental 
fatigue and it has been shown to be  sensitive to many natural interventions [19,27–30]. Two minutes 
each of Serial 3s and 7s subtractions is first completed and followed immediately by 5 minutes of 
Rapid Visual Information Processing. Mental fatigue is self-rated after each completion of the three 
tasks. In the current study the tasks were repeated 3 times, giving a total of 30 minutes of continuous 
demanding cognitive task performance. 
Serial 3s and 7s subtractions—At the start of the 2 minutes task a standard instruction screen 
informs the participant to count backwards in 3s or 7s as quickly and accurately as possible, using 
the keyboards linear number keys to enter each response. Participants were instructed verbally at the 
outset that if they were to make a mistake they should carry on subtracting from the new incorrect 
number with subsequent responses scored as correct in relation to the new number. To begin, a 
random starting number between 800 and 999 was presented on the computer screen, which was 
cleared by the entry of the first response. Each three-digit response was represented on screen by 
asterisks and pressing the enter key signalled the end of each response and cleared the three asterisks 
from the screen. Outcomes were the total number of correct subtractions and the number of incorrect 
responses. 
Rapid Visual Information Processing (RVIP) task—The RVIP task required the participant to 
monitor a continuous series of single digits for targets of three consecutive odd or even numbers. The 
white digits are presented on the black computer screen at the rate of 100 per minutes; with eight 
correct target strings in each minute presented in pseudo-random order. The participant responded 
to the detection of a target string by pressing the appropriate response button as quickly as possible. 
The RVIP was scored for the % target strings correctly detected, false alarms and the average reaction 
time (ms) for correct detections. 
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2.4.8. Peg and Ball 
Two configurations of wooden peg (×3) and ball (×3; blue, green and red) diagrams were 
displayed, on screen, with the top diagram denoting the ‘goal’ configuration of balls on pegs. 
Participants were required to rearrange the balls on the ‘starting’ configuration below this to match 
the ‘goal’ configuration. They were instructed to do this in the least number of moves possible. The 
task was scored for average thinking time (ms), average completion time (ms) and errors (total 
number of moves in excess of minimum required to complete all trials). 
2.4.9. Delayed Word Recall 
Participants were informed, via a computerized instruction page, that they had 60 seconds to 
note down as many of the words from the list presented at the beginning of the task battery as they 
could remember. The task outcomes were the number of correctly recalled words and the number of 
incorrect words. 
2.4.10. Delayed Name to Face Recall 
The target faces presented at the beginning of the battery were displayed on the screen one at a 
time. Below each face was a list of 4 forenames and a list of 4 surnames. Participants used the mouse 
to select the forename and surname that they believed were associated with each face as presented at 
the beginning of the assessment. The task outcomes comprised % accuracy for overall correct 
forenames and correct surnames and reaction time (ms). 
2.4.11. Delayed Picture and Word Recognition 
Word and picture recognition were completed separately but both required participants to 
differentiate, by pressing ‘yes’ or ‘no’ on the response box, between the 15 target words and pictures 
presented at the beginning of the test battery and 15 randomly interspersed decoy words and 
pictures. The tasks took ~2 minutes to complete and were scored for % of correctly recognized 
words/pictures and reaction time (ms). 
 
All of the computerized cognitive assessments were identical, with the exception of the 
presentation of randomly generated parallel versions of each task. The individual tasks making up 
the cognitive/mood assessment, alongside the timelines of each assessment are shown in Figure 2. 
Figure 2 also shows the contribution of individual tasks to the measures that were derived by 
collapsing the data from individual tasks into cognitive domain factor scores representing the 
average speed (ms) of performance (Speed of Attention, Speed of Memory) or average (% correct) 
accuracy (Accuracy of Attention, Working Memory, Secondary Memory) of the attention tasks and 
working/episodic memory tasks within the battery. Two global performance measures were also 
calculated; ‘Speed of Performance’ and ‘Accuracy of Performance.’ These comprised averaged Z 
scores for speed and accuracy data respectively (for all tasks that collected such data). The composite 
measures have previously been shown to be sensitive to nutritional interventions ([23,31]). The task 
running order and contribution to cognitive factors and global measures are shown in Figure 2 below. 
2.5. Cerebral Blood-Flow (via NIRS) Assessment 
Forty one of the participants took part in an additional NIRS assessment, with CBF parameters 
(oxygenated hemoglobin [oxy-Hb], deoxygenated hemoglobin [deoxy-Hb], total-hemoglobin [total-
Hb—the sum of oxy-Hb and deoxy-Hb, a marker of overall CBF] and % oxygen saturation [% oxy]) 
measured in the frontal cortex using NIRS at rest and during cognitive task performance. Each 
assessment comprised a 5 minute pre-dose resting measurement and a post-dose assessment 
commencing either at 120 or 150 minutes post-dose. The post-dose assessment comprised a 5 minutes 
resting measurement followed by 27 minutes (3 repetitions) of performing the Cognitive Demand 
Battery tasks (Serial 3s – 2 minutes, Serial 7s – 2 minutes, RVIP—5 minutes) all of which activate the 
frontal cortex. The NIRS assessment is shown in Figure 3. 
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Figure 3. Near-infrared spectroscopy (NIRS) assessment timeline. Each NIRS assessment comprised 
a pre-dose resting baseline and a post-dose assessment taking place between the 60– and 180 minutes 
post-dose cognitive assessments, as shown here. The post-dose assessmentcomprised a 5 minutes 
resting period, followed by three repetitions of the Cognitive Demand Battery tasks (27 minutes), all 
of which have been shown to sensitively modulate CBF parameters in the frontal cortex previously. 
2.5.1. Near-Infrared Spectroscopy (NIRS) 
Cerebral blood-flow (CBF) parameters and hemodynamic responses during task performance 
were monitored using a quantitative NIRS system (OxiplexTS Frequency-Domain Near-Infrared 
Tissue Oximeter; ISS, Inc., Champaign, IL, USA). NIRS provides a proxy measure of CBF parameters 
and has been shown to sensitively measure resting CBF and hemodynamic responses in humans 
during differing levels of brain activation [32]. The system employed here gives absolute 
measurements of absorption of near-infrared light emitted at two distinct wavelengths. This allows 
the quantification of oxy-Hb and deoxy-Hb. These values are then used to determine total-Hb (oxy-
Hb + deoxy-Hb) and % oxy (oxy-Hb/total-Hb × 100). This system is ideal for quantifying acute 
changes in hemodynamic responses over an extended period (i.e., with intermittent testing 
throughout one visit) and in a chronic context (here comparing CBF parameters between Day 1 and 
Day 56). 
Light was emitted at 691 and 830 nm by optical fibers glued in pairs to four prisms (eight fibers 
in total) that were separated from the collector bundle, also glued to a prism, by 2.0-, 2.5-, 3.0- or 3.5 
cm. Each of the emitter and collector bundle prisms were embedded into a flexible polyurethane resin 
to form a sensor with the overall dimensions of 7.6 cm × 2.5 cm × 0.3 cm. Identical sensors were 
attached to either side of the forehead of participants with medical tape and secured in place with a 
self-adhering bandage. The sensors were positioned so that the bottom edge was level with the top 
of the participants’ eyebrows and the middle edge touching at the midline of the forehead. Data were 
collected at a rate of 5 Hz. 
2.6. Procedure 
Testing took place in a suite of testing facilities with participants visually isolated from each 
other. Participants attended the laboratory on 3 separate occasions; an introductory visit between 1 
and 14 days before the first day of treatment and two testing days (Day 1 and Day 56 of treatment). 
The Introductory visit to the laboratory comprised—briefing on requirements of the study, 
obtaining of informed consent, health screening, completion of the Caffeine Consumption 
Questionnaire (CCQ) and State-Trait Anxiety Inventory (STAI) trait subscale, training on the 
cognitive and mood measures and collection of demographic data. 
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For the two subsequent laboratory-based testing sessions (Day 1, Day 56) participants attended 
the laboratory at 8:30 am having consumed a standardized breakfast of cereal and toast at home no 
later than an hour before arrival. They had refrained from alcohol for 24 hours and caffeine for 18 
hours before each visit. On arrival on each day, participants completed the STAI state subscale and 
the computerized cognitive assessment (as per Figure 2). The participants who were taking part in 
the CBF study (maximum 2 participants per day) were then equipped with the NIRS for a 5-minute 
resting measurement of CBF parameters. Thirty minutes after the initial cognitive assessment 
participants consumed their treatment for that day. Three further cognitive assessments, identical to 
the pre-dose assessment commenced at 1 hour, 3 hours and 5 hours post-dose, with the CBF subset 
of participants undergoing their post-dose NIRS assessment between the 1 h and 3 h cognitive 
assessments (i.e., commencing at either 120 or 150 min post-dose). Participants were given a 
standardized lunch at approximately 2:00 pm. Testing was identical on Day 56 with the exception 
that—following the completion of Day 1 testing, participants were provided with the treatment they 
would be consuming between study days and a treatment diary; and following the completion of 
testing on Day 56, participants were asked to guess which treatment they had consumed and they 
returned their remaining treatment and diary for analysis of compliance and adverse events. The 
testing day timeline is shown in Figure 4. 
 
 
 
 
Figure 4. Testing session timeline on Day 1 and Day 56. Cognitive assessments were completed at 
8:30 am (pre-dose) and 60-, 180- and 300 minutes post-dose. Cerebral blood flow measures were taken 
from a subset of participants at baseline and then again at post-dose between the 60- and 180 minutes 
cognitive assessments. A standardized lunch was provided at ~2:00 pm. 
2.7. Analysis 
2.7.1. Cognitive and Mood Outcomes 
The data from the individual tasks was collapsed into five separate cognitive factor scores 
(accuracy measures = average % correct: speed measures = average reaction time in ms) and two 
global performance scores (average of accuracy or speed Z scores) as shown in Figure 2. The 
outcomes from the individual tasks shown in Figure 2 were also analyzed as secondary outcomes. 
The 3 repetitions (per assessment) of the Cognitive Demand Battery also returned the outcomes 
described above for the mental fatigue visual analogue scale, RVIP task, Serial 3sand Serial 7s. 
 
Acute (Day 1) effects—In order to explore the acute effects of ZA, data from the Day 1 post-dose 
assessments at 1 hour, 3 hours and 5 hours were baseline adjusted with regards the pre-dose baseline 
data collected on Day 1 and entered into a two way (treatment [placebo, ZA] × assessment [1 hour, 3 
hours, 5 hours]) ANOVA. Analyses of the Cognitive Demand Battery outcomes were by three-way 
(treatment [placebo, ZA] × assessment [1 hour, 3 hours, 5 hours] × repetition [1, 2, 3]) ANOVA. 
 
Chronic (Day 56) effects—In order to explore the chronic effects of ZA after 56 days 
administration, data from the pre-dose and 1 hour, 3 hours and 5 hours post-dose assessments on 
Day 56 were baseline adjusted with respect to the Day 1 pre-dose baseline data and analyzed via two-
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way (treatment [placebo, ZA] × assessment [pre-dose, 1 hour, 3 hours 5 hours]) ANOVA to compare 
performance between treatments. Analyses of the Cognitive Demand Battery outcomes were by 
three-way (treatment [placebo, ZA] × assessment [1 hour, 3 hours, 5 hours] × repetition [1, 2, 3]) 
ANOVA. 
For both the acute and chronic analyses, planned comparisons between data from each condition 
during each assessment were also conducted using t-tests, utilizing Mean Squares Error (MSE) from 
the ANOVA. These comparisons were Bonferroni adjusted. Only those planned comparisons relating 
to an outcome that generated a significant ANOVA result are reported.  
Day 1 baseline differences between placebo and ZA were explored using t-tests for those 
measures that had a single repetition and with reference to the main treatment effect of two-way 
ANOVAs (repetition [3] × treatment [placebo/ZA]) for those measures (Cognitive Demand Battery 
outcomes) that had three repetitions. 
2.7.2. Frontal Cortex Cerebral Blood Flow analysis 
There were three separate analyses of data for these CBF parameters: 
 
Global CBF effects on Day 1 and Day 56—The effects of ZA on global CBF parameters in the 
absence of task related brain activation (i.e., resting CBF) were analysed with unadjusted averaged 
data from the pre and post-dose resting assessments on Day 1 and Day 56. The analysis was by three-
way ANOVA (pre/post dose × Day 1/56 × treatment) of averaged data from each 5 minute rest period. 
Bonferroni adjusted post-hoc comparisons were then carried out between ZA and placebo as 
appropriate. This analysis also provided a test of baseline differences between groups on Day 1 and 
at rest (post-dose) on Day 1/Day 56. 
Acute (Day 1) effects during brain activation—Post-dose data were averaged across 14 epochs 
(rest: 2 × 2.5 minutes, Serial 3s subtractions: 3 × 2 minutes, Serial 7s subtractions: 3 × 2 minutes, RVIP: 
6 × 2.5 minutes: See Figures 9 and 10). The acute effects of a single dose of ZA on CBF parameters on 
Day 1 were measured as the change in CBF parameters during each 2 or 2.5 minute epoch of the 32-
minute post-dose assessment, baseline adjusted to the pre-dose resting baseline. The analysis of 
change from baseline data was by two-way ANOVA (treatment [ZA/placebo] × epoch [14 × 2/2.5 
minutes epochs). Bonferroni adjusted planned comparisons were then carried out between ZA and 
placebo during each epoch of the Day 1 post-dose assessment . Only those planned comparisons 
associated with a significant treatment related effect (multivariate or between-subjects) are reported 
below. 
Hemodynamic responses on Day 1 and Day 56—In the absence of any effect on global blood-
flow on Day 1/56 (see results below) the effects of ZA on hemodynamic responses (the CBF response 
to local brain activation; i.e., how much blood flow and oxygenation change in response to increased 
activity) were measured as changes in CBF parameters during each 2/2.5 minutes epoch of active task 
performance and baseline adjusted to the respective 5 minutes resting period immediately before 
task performance. The analysis of change from resting baseline data was performed by three-way 
ANOVA (treatment [ZA/placebo] × day [1/56] × epoch [12 × 2/2.5 minutes epochs]). Bonferroni 
adjusted planned comparisons were then carried out as described above. 
3. Results 
3.1. Cognitive Function and Mood 
3.1.1. Baseline Differences 
There was a significant difference between groups in terms of self-rated mental fatigue during 
the Cognitive Demand Battery, with participants in the ZA group rating themselves as more mentally 
fatigued than placebo [F(1, 79) = 8.10, p = 0.006] during the Day 1 pre-dose assessment. Participants 
in the ZA group also made significantly more false alarms on the RVIP task during the Day 1 pre-
dose assessment compared to placebo [F(1, 79) = 7.34, p = 0.008]. 
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There were no other significant Day 1 baseline differences on any demographic, cognitive, mood 
or CBF measure. 
3.1.2. Acute Effects of ZA after a Single Dose (Day 1) 
Cognitive factors and global speed and accuracy outcomes—Consumption of a single dose of 
ZA lead to a significant improvement on the Speed of Attention factor (main effect—[F(1, 75) = 4.42, 
p = 0.039]). Reference to planned comparisons of data from each assessment showed that the speed 
of attention task performance was enhanced at both 1 hour [t(150) = 3.17, p = 0.005] and 3 hours [t(150) 
= 4.89, p < 0.001] post-dose. See Figure 5 panel A/B. In support of this there was a trend towards 
increased speed across the global Speed of Performance factor [F(1, 79) = 2.91, p = 0.092]. 
In terms of single tasks, there was a significant treatment × assessment interaction with regards 
the number of errors on the Delayed Word Recall task [F(2, 158) = 3.36, p = 0.037] with participants 
generating significantly fewer errors following ZA during the 1 hour post-dose assessment [t(158) = 
2.56, p = 0.011]. In contrast, participants performed the Name to Face task less accurately in terms of 
% correct following ZA [F(1, 79) = 4.35, p = 0.04] with this effect evident at 1 hour [t(158) = 2.51, p = 
0.039] and 3 hours [t(158) = 2.55, p = 0.035]. See Figure 5 panel C/D. There were also significant 
treatment × assessment interactions for the Bond-Lader content score and Peg and Ball errors but 
planned comparisons showed that there was no significant difference between treatments during any 
of the three assessments. 
 
Figure 5. Effects on Speed of Attention. Top: Acute (Day 1) effects of a single dose of ZA on the Speed 
of Attention factor showing the main effect (panel A) and the planned comparisons (panel B) 
conducted on data from each post-dose assessment (i.e., 1-, 3- and 5-hour post-dose). Bottom: acute 
effects of ZA on the individual cognitive tasks, Delayed Word Recall errors (panel C) and Name to 
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Face recall accuracy (panel D). Data (mean and SEM) is change from pre-dose baseline. * = p < 0.05. n 
= 42/35 (ZA/placebo) for panel A and B and 42/39 for panel C and D. 
Cognitive Demand Battery—The accuracy of performance on the RVIP task was significantly 
improved following ZA in terms of reduced false alarms (main effect: [F(1, 75) = 5.25, p =0.025]). See 
Figure 6. Reference to the planned comparisons showed that this effect was significant during the 1 
hour [t(300) = 2.43, p = 0.046] and 5 hours [t(300) = 2.95, p = 0.011] post-dose assessments. It is notable 
that there was a strong trend towards improved speed of performance on the RVIP [F(1, 75) = 3.80, p 
= 0.055] confirming that the increased accuracy was not due to a speed accuracy trade-off. 
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Figure 6. Effects on the Rapid Visual Information Processing (RVIP) task. Acute (Day 1) effects of a 
single dose of ZA on the RVIP task from the Cognitive Demand Battery outcomes. Panel A shows the 
main effect and panel B shows the planned comparisons conducted using data from each post-dose 
assessment (i.e., 1-, 3- and 5-hour post-dose). Data (mean and SEM) are change from pre-dose 
baseline. * = p < 0.05 significant difference to placebo at that time point. n = 42/35 (ZA/placebo). 
3.1.3. Chronic Effects of ZA after 56 Days Treatment 
Cognitive factors and global speed and accuracy outcomes—There was a significant beneficial 
effect of ZA treatment on the global Speed of Performance measure [F(1, 76) = 4.28, p = 0.042]. See 
Figure 7. Planned comparisons of data from each assessment showed that participants performed 
significantly faster across the timed tasks during the pre-treatment [t(228) = 2.60, p = 0.02], 1 hour 
[t(228) = 3.70, p < 0.001] and 3 hours [t(228) = 2.92, p = 0.012] post-dose assessments. There were no 
significant effects of ZA with regards the other cognitive factor scores. However, it is noteworthy that 
there was a trend towards improved Speed of Attention across assessments on Day 56 [F(1,71) = 3.17, 
p = 0.079]. 
With respect to individual tasks, ZA resulted in an interaction between treatment and 
assessment for the speed of performing the Peg and Ball task [F(3, 222) = 4.71, p = 0.003]. Reference to 
the planned comparisons showed that the speed of performing the task was slower during the pre-
dose assessment [t(222) = 2.91, p = 0.016] but numerically faster during later assessments. 
 
Cognitive Demand Battery—ZA resulted in reduced ratings of mental fatigue during all of the 
assessments on Day 56 (main effect: [F(1,76) = 8.01, p = 0.006] and a treatment × assessment interaction 
[F(2, 465) = 4.09, p = 0.019]. Planned comparisons showed that, following ZA, mental fatigue was 
significantly lower during the pre-dose assessment [t(465) = 4.49, p < 0.001] and at 1 hour [t(465) = 
Nutrients 2019, 11, 3022 13 of 21 
 
7.70, p < 0.001], 3 hours [t(465) = 5.80, p < 0.001] and 5 hours [t(465) = 9.20, p < 0.001] post-dose. There 
was also a treatment × assessment interaction with regards the number of correct Serial 3s 
subtractions [F(3, 450) = 6.42, p < 0.001], with planned comparisons showing that this was a 
consequence of a significant improvement following ZA during the 3 hours post-dose assessment 
[t(450) = 3.09, p = 0.008]. See Figure 8. 
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Figure 7. Effects on Speed of Performance. Chronic effects of 56-days administration of ZA on the 
global Speed of Performance measure (calculated as the average reaction time Z score for the 9 timed 
tasks). Panel A shows the main effect and panel B shows the planned comparisons conducted using 
data from each post-dose assessment (i.e., 1-, 3- and 5-hour post-dose). Data (mean and SEM) are 
change from pre-dose baseline. * = p < 0.05 significant difference to placebo at that time point. n = 39/39 
(ZA/placebo). 
Whilst not reaching significance, it is noteworthy that, in light of the reduced hemodynamic 
responses seen during the RVIP task in the concomitant NIRS study (see below), there were trends 
towards improved performance on this task in terms of reduced false alarms [F(1, 71) = 3.24, p = 0.076] 
and faster performance [F(1, 71) = 3.74, p = 0.057]. This confirms that the hemodynamic changes in the 
NIRS assessment described below were not associated with any cognitive decrements. 
 
Data (means, SEMs and ANOVA F and p values) for the cognitive function analyses are 
presented in online supplementary Table S1 (factors and global measures), Tables S2 and S3 
(individual task outcomes), Tables S5 and S6 (Cognitive Demand Battery). There was no effect of 
treatment on ratings of anxiety as assessed by the STAI Inventory or on the three factors derived from 
the Bond-Lader scales. 
Data (means, SEMs and ANOVA F and p values) for the mood measures are presented in online 
supplementary Tables S4 (Bond-Lader Mood Scales) and S7 (STAI). 
Nutrients 2019, 11, 3022 14 of 21 
 
Mental Fatigue
-10
0
10
20
Assessment
Pre-dose 1 hr 3 hr 5 hr
%
 (a
lo
ng
 V
AS
)
im
pr
ov
em
en
t
*
*
* *
Serial 3 
subtractions
N
um
be
r c
or
re
ct
0
2
4
6
8
10
Assessment
Pre-dose 1 hr 3 hr 5 hr
im
pr
ov
em
en
t
*
0
5
10
15 A. B.
C.
 
Figure 8. Chronic effects of ZA on Mental Fatigue and Serial 3s subtraction performance. Panel A 
shows the main effect on mental fatigue and panel B shows the planned comparisons conducted on 
data from each post-dose assessment (i.e., 1-, 3- and 5-hour post-dose). The bottom panel depicts the 
chronic effects of ZA on the Serial 3s subtraction task. Data (mean and SEM) are change from pre-
dose baseline. * = p < 0.05 significant difference to placebo. n = 39/39 (ZA/placebo). 
3.2. NIRS-CBF 
3.2.1. Global Changes in Resting CBF Parameters 
There was no significant effect of ZA on gross levels of oxy-Hb, deoxy-Hb or their sum (total-
Hb) or ratio (% O2) measured during the pre-dose and post-dose resting periods on Day 1 and Day 
56. 
3.2.2. Acute Effects on Day 1 
Analysis of change from pre-dose baseline data demonstrated that ZA resulted in significantly 
reduced oxy-Hb and total-Hb (i.e., CBF) during task performance (Total-Hb (multivariate) [F(13, 25) 
= 2.85, p = 0.012]−oxy-Hb [F(13, 481) = 1.95, p = 0.025]). There was no significant effect during the post-
dose rest period. Planned comparisons during each epoch are presented in Figure 9. Reference to the 
figures shows that the effect is predominantly driven by a decreased hemodynamic response in terms 
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of oxy-Hb, with this effect only significant during the RVIP attention task. There was no significant 
effect on deoxy-Hb or % O2. 
 
Figure 9. Acute effects on cerebral blood flow (CBF) parameters after the first dose of ZA. The figures 
show pre-dose resting baseline adjusted data (µM; mean + SEM) where placebo is compared to ZA at 
each 2/2.5 minutes epoch of pre-task rest and  task performance during Serial 3s, Serial 7s and the 
Rapid Visual Information Processing tasks. Asterisks indicate significance on the Bonferroni adjusted 
planned comparisons conducted on data from each epoch. * = p < 0.05. n = 20/21 (ZA/placebo). 
3.2.3. Acute (Day 1) and Chronic (Day 56) Effects on Hemodynamic Responses to Brain Activation 
Whilst consumption of ZA had no effect on global CBF parameter at rest (see above) it did result 
in significant modulation of the hemodynamic response to brain activation during task performance 
on both Day 1 and Day 56 (treatment × epoch interactions—oxy-Hb [F(11, 429) = 2.21. p = 0.013], % O2 
[F(11, 429) = 2.38, p = 0.007]—main effect, total-Hb [F(1, 39) = 4.43, p = 0.042]). The pattern was for a 
global reduction in CBF driven by the reduction in oxygenated hemoglobin, which itself was most 
pronounced during the RVIP attention task. Oxygen saturation (% O2); reflecting the ratio of oxy-Hb 
and deoxy-Hb, was also significantly decreased but only during the RVIP task. Planned comparisons 
during each epoch are presented in Figure 10. 
 
Data (means, SEMs—t and p values at each epoch) for the NIRS CBF-parameter analyses are 
presented in online supplementary Tables S8 (acute effects on Day 1), S9 (pre/post-treatment resting 
CBF on Day 1/56) and S10 (acute and chronic hemodynamic response). 
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Figure 10. Effects of ZA on hemodynamic responses to brain activation (task performance) on Day 1 
and Day 56 of treatment. The figures show data (mean + SEM) from each epoch of task performance 
(i.e., 7–32 min), baseline adjusted to the 5 min rest period immediately before the tasks commenced. 
Asterisks indicate significance on the Bonferroni adjusted planned comparisons; where placebo is 
compared to ZA at each epoch. * = p < 0.05. Serial 3s, Serial 7s and the Rapid Visual Information 
Processing task. n = 20/21 (ZA/placebo). 
3.2.4. Cognitive Performance 
There were no significant acute or chronic treatment related changes in the performance of tasks 
(Serial 3s, Serial 7s, RVIP), during the NIRS assessment. Data (means and SEM) for the Cognitive 
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Demand Battery tasks during the NIRS assessment are presented in supplementary Tables S11 and 
S12. 
4. Discussion 
The results demonstrate that a single dose and 56-days administration of Zanthoxylum armatum 
DC. MCT oil extract (ZA; product name SaraPEPP™ Nu) lead to significant improvements in 
cognitive function and modulation of cerebral blood flow (CBF) parameters. 
With regards cognitive function, the most striking finding was an increased speed of task 
performance. This was seen in terms of significantly faster attention task performance (Speed of 
Attention) on Day 1 and significantly faster performance across all tasks (Speed of Performance) on 
Day 56. These findings were also supported by corresponding trends towards faster task performance 
on both days (Speed of Performance on Day 1 and Speed of Attention on Day 56). Improvements 
were also seen within the Cognitive Demand Battery outcomes. Firstly, improved accuracy of Rapid 
Visual Information Processing (RVIP) performance, in terms of false alarms after a single dose (Day 
1), was observed. Reduced ratings of Mental Fatigue across all assessments and increased correct 
Serial 3 seconds were also evident during the 3 hours post-dose assessment, on Day 56. Of note, the 
beneficial effects of ZA on Speed of Performance and Mental Fatigue on Day 56 were evident both 
before and, to a greater extent, after the consumption of the day’s treatments, suggesting that the 
beneficial effects of ZA, at least in part, were related to chronic consumption. 
The predominant cognitive effects were a general increase in speed of processing, rather than 
domain specific changes and these might be expected to correlate with a similar general change in 
CBF during task performance. With reference to the NIRS results, whilst ZA had no effect on gross, 
resting CBF following either a single dose or 56-days administration, it did result in modulation of 
several hemodynamic parameters during the performance of tasks that activate the pre-frontal cortex; 
both following a single dose and following 56-days administration. Broadly, the pattern of results 
was for reduced hemodynamic responses during task performance across both days. For the analysis 
combining data from Day 1 and Day 56 this was seen in terms of reduced oxygenated hemoglobin, 
reduced total hemoglobin (a proxy for overall CBF) and reduced % oxygenation, with these effects 
seen predominantly during the RVIP attention task. A further analysis of CBF data (task × treatment 
× day) confirmed that the significant effects seen here were task dependent and primarily seen during 
the RVIP task. It is notable that performance of the RVIP task has previously been shown to activate 
the prefrontal cortex [33,34].Interestingly, the ANOVAs here did not show any interactions between 
visit and treatment; suggesting that the hemodynamic effects during task performance were similar 
after acute and chronic supplementation. However, it might be noteworthy that the pattern of 
modulation after 56-days administration could be described descriptively as being stronger, on the 
basis of the number of epochs that saw a significant difference between treatments. 
One important point here is that the reduced hemodynamic response, particularly during the 
RVIP focused attention task, was not associated with poorer cognitive function. Indeed, as well as 
the significant improvements in the speed of performing the attention tasks on Day 1 and all of the 
timed tasks on Day 56, performance on the RVIP task for the full cohort was more accurate on Day 1 
with trends towards increased accuracy and faster speed on this task on Day 56. Taken together, these 
findings strongly suggest that the pattern of hemodynamic effects seen here reflect improved 
physiological brain function. It would, of course, be interesting to explore the nature and spatial 
properties of the brain function effects seen here with alternative imaging techniques. NIRS only 
provides proxy measures of CBF and these can be conflated with changes in cerebral blood volume 
and cerebral rates of oxygen metabolism. In common with NIRS, most other brain imaging 
techniques also interpret proxy markers. However, investigations of ZA’s effects on regional 
electrophysiological activity (e.g., via Electroencephalography (EEG)), gross cerebral blood flow 
parameters (e.g., via Trans-Cranial Doppler) or the spatial resolution of any brain function effects (via 
Functional Magnetic Resonance Imaging (FMRI) would be of interest in future trials. Interestingly, 
recently developed neuroimaging techniques, such as Event-related optical signal (EROS) offer a 
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direct measure of neuronal cellular activity and might be useful in disentangling any changes in local 
neuronal activity and blood flow. 
Interestingly, the CBF results in the current study bear a striking resemblance to those seen 
following the consumption of dietary nitrate [35]. In this previous study, which involved similar 
methodology as employed here, the reduction in CBF following a single dose of nitrate-rich beetroot 
juice was only seen during the RVIP task. There were no nitrate related effects on CBF during the 
serial subtraction tasks but improved performance on the Serial 3s subtraction task was seen 
nonetheless. In this earlier study it was noted that the RVIP task is a less cognitively demanding task 
and that the pattern of reductions in CBF represented an exaggeration of the typical response to 
reduced demand. The authors also attributed the findings to increased neural efficiency related to a 
nitrate related increase in the synthesis of the nitric oxide, with an attendant enhancement of cellular 
metabolic processes [35]. 
In terms of mechanisms underpinning the effects seen in the current study, previous research 
suggests that both the gastrointestinal effects of Daikenchuto, which contains hydroxy-alpha-
sanshool from Z. piperitum [13] and the learning and memory effects of ZA in rodents [12] may be 
underpinned by increased cholinergic activity. Indeed, monoterpenes, which are represented in ZA 
extracts at significant levels, have been shown to have consistent cholinesterase inhibitory properties 
[36,37] and to exert beneficial cognitive effects [20]; including at doses as low as 25 µL [38]. A 
cholinergic mechanism certainly could be responsible for the cognitive effects seen here, although the 
pattern here on Day 56 was for a speeding of performance across cognitive domains; suggesting a 
general improvement in neural efficiency and processing speeds rather than the focused cognitive 
benefits to memory/attention that cholinergic agents are typically associated with. It is, however, 
unlikely that the interactions with cannabinoid CB1 and CB2 receptors attributed to some sanshools 
(specifically γ-sanshool) [14] played any role here, as preliminary screening demonstrated that the 
extract administered here did not exhibit any cannabinoid receptor binding activity (data not 
presented but available on request). 
One alternative possibility then, is that the cellular ion channel mechanisms that drive the 
sensory tingling-numbness following topical/oral application of hydroxy α-sanshool; namely 
interactions with TRP and KCNK ion channels, may also be responsible for the cognitive and CBF 
effects seen here. In this respect it is notable that structurally similar alkamides have been shown to 
have good bioavailability and can readily cross the blood brain barrier [5]. Recent evidence also 
shows that the TRPV1 vanilloid receptors with which hydroxy α-sanshool interacts are widely 
distributed in the brain. Indeed, TRPV1 has a key role in the regulation of neuronal excitability and 
synaptic plasticity, including long-term potentiation, potentially mediated by glutamate release [17]. 
Similarly, several members of the KCNK two-pore domain potassium ion channel family that are 
inhibited by hydroxy α-sanshool, specifically TASK-1, TASK-3 and TRESK [4] are also expressed, 
often as TASK-1/TASK-3 heterodimers, throughout multiple brain regions, with particular 
concentration in the cerebellum, somatic motor-neurons and hypothalamus. These channels 
contribute to the excitability of distinct populations of neurons [18]. As an example, TASK-1 and 
TASK-3 channels contribute to the excitability of several types of hippocampal neurons, including 
CA1 pyramidal cell and inhibitory interneurons [39] and modulate the excitability of the key 
acetylcholine producing basal forebrain cholinergic neurons which drive elements of cortical arousal 
[40]. Clearly, interactions with neuronal mechanisms such as these might be expected to have a 
general, rather than cognitive-domain specific effect in terms of neural activation/efficiency and 
hemodynamic responses to brain activation. 
5. Conclusions 
In conclusion, a ZA extract rich in hydroxy α-sanshool resulted in global improvements in the 
speed of performing cognitive tasks, suggesting enhanced processing speed. ZA also resulted in a 
decreased hemodynamic response in the frontal cortex to cognitive task-mediated activation of this 
brain region. These effects can reasonably be interpreted as reflecting a ZA-related increase in neural 
efficiency, particularly during attention task performance. Whilst the exact mechanisms driving these 
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effects are unclear at present, future research should explore the possibility that hydroxy α-sanshool 
is the active principal, potentially acting via interactions with neuronal ion channels. 
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